Placeholder Banner

BIO Files Amicus Brief Supporting Rehearing of Case Addressing Patent Rights and America Invents Act (AIA) at the U.S. Court of Appeals for the Federal Circuit

July 14, 2017

BIO filed an amicus brief in support of a petition to rehear Helsinn Healthcare S.A. v. TEVA Pharmaceuticals USA, Inc., TEVA Pharmaceutical Industries Ltd. at the U.S. Court of Appeals for the Federal Circuit.

Because modern biotechnological products commonly involve lengthy, resource- and investment-intensive development periods, BIO members depend heavily on robust patent rights and a fair system for adjudicating their validity. Accordingly, it’s important to have certainty regarding the types of transactions and what must be publicly disclosed about those transactions to qualify as invalidating activities under the on-sale bar of the America Invents Act (AIA).

Related Resources
2016-1284, -1787 The Biotechnology Innovation Organization (BIO) As Amicus Curiae Supporting Rehearing En Banc
BIO Brief supporting rehearing en banc in Helsinn v. Teva Phamaceuticals
Discover More
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…
BIO and AUTM have filed an amicus brief in petition for a writ of certiorari the in American Axle & Manufacturing, Inc., v. Neapco Holdings LLC, et al., at the Supreme Court of the United States. BIO and AUTM are concerned that…